Wave Life Sciences Ltd. — fact timeline

Wave Life Sciences Ltd. reported financial results for quarter ended March 31, 2026.

“On April 28, 2026, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026.”

Wave Life Sciences Ltd. entered into Implementation Agreement with Wave Life Sciences, Inc. (Wave-Delaware) valued at Exchange all Wave-Singapore ordinary shares for Wave-Delaware common stock on a one-for-one basis; R (effective 2026-04-15).

“In order to complete the Redomiciliation, the boards of directors of each of Wave-Singapore and Wave Life Sciences, Inc., a Delaware corporation (“ Wave-Delaware ”), approved the entry by Wave-Singapore and Wave-Delaware, respectively, into an Implementation Agreement (the “ Implementation Agreement ”). The Implementation Agreement was executed by Wave-Singapore and Wave-Delaware on April 15, 2026 and provides for a statutory procedure known as a scheme of arrangement (the “ Scheme of Arrangement ”) to be implemented by Wave-Singapore and Wave-Delaware under Singapore law, subject to approval of the shareholders of Wave-Singapore and the High Court of the Republic of Singapore.”

Wave Life Sciences Ltd. entered into Underwriting Agreement with Jefferies LLC, Leerink Partners LLC and BofA Securities, Inc. valued at approximately $402.5 million (effective 2025-12-09).

“On December 9, 2025, Wave Life Sciences Ltd. (the “Company,” “we” or “us”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC and BofA Securities, Inc., as representatives of the several underwriters named therein”

Wave Life Sciences Ltd. reported financial results for the quarter ended March 31, 2024.

“On May 9, 2024, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2024.”

Wave Life Sciences Ltd. entered into Underwriting Agreement with J.P. Morgan Securities LLC and Leerink Partners LLC, as representatives of the several underwriters valued at $5.00 per Share (effective 2023-12-06).

“On December 6, 2023, Wave Life Sciences Ltd. (the “Company”, “we” or “us”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Leerink Partners LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”) by the Company of an aggregate of 20,000,000 of the Company’s ordinary shares, no par value (the “Firm Shares”), at a public offering price of $5.00 per Share.”

Wave Life Sciences Ltd. reported the third quarter ended September 30, 2023 results: net income Cash and cash equivalents of $140 million as of September 30, 2023.

“On November 9, 2023, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended September 30, 2023.”

Wave Life Sciences Ltd. shareholders approved Shareholders approved on a non-binding, advisory basis only, the compensation of the Company’s named executive officers at the 2023-08-01 meeting.

“Shareholders approved on a non-binding, advisory basis only, the compensation of the Company’s named executive officers”

Wave Life Sciences Ltd. shareholders approved Shareholders approved a general authorization for the directors of the Company to allot and issue ordinary shares of the Company at the 2023-08-01 meeting.

“Shareholders approved a general authorization for the directors of the Company to allot and issue ordinary shares of the Company”

Wave Life Sciences Ltd. shareholders approved Shareholders approved the amendment to the Company’s 2019 Employee Share Purchase Plan at the 2023-08-01 meeting.

“Shareholders approved the amendment to the Company’s 2019 Employee Share Purchase Plan”

Wave Life Sciences Ltd. shareholders approved Shareholders approved the amendment to the Company’s 2021 Equity Incentive Plan, as amended at the 2023-08-01 meeting.

“Shareholders approved the amendment to the Company’s 2021 Equity Incentive Plan, as amended”

Wave Life Sciences Ltd. shareholders approved Shareholders approved the Company’s payment of cash and equity-based compensation to the Company’s non-employee directors for their service on the Board of Directors and its committees at the 2023-08-01 meeting.

“Shareholders approved the Company’s payment of cash and equity-based compensation to the Company’s non-employee directors for their service on the Board of Directors and its committees”

Wave Life Sciences Ltd. shareholders approved Shareholders approved the re-appointment of KPMG LLP to serve as the Company’s independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2023, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP’s remuneration for serv at the 2023-08-01 meeting.

“Shareholders approved the re-appointment of KPMG LLP to serve as the Company’s independent registered public accounting firm and independent Singapore auditor for the year ending December 31, 2023, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP’s remuneration for services provided through the date of the Company’s 2024 Annual General Meeting of Shareholders”

Wave Life Sciences Ltd. shareholders approved Shareholders re-elected nine of the Company’s existing directors to the Board of Directors for a term ending on the Company’s 2024 Annual General Meeting of Shareholders and until his or her successor is duly elected and qualified at the 2023-08-01 meeting.

“Shareholders re-elected nine of the Company’s existing directors to the Board of Directors for a term ending on the Company’s 2024 Annual General Meeting of Shareholders and until his or her successor is duly elected and qualified”

Wave Life Sciences Ltd. reported the quarter ended June 30, 2023 results: revenue $22.1 million, net income a net loss of $21.1 million.

“under the company’s collaboration with GSK, which became effective January 27, 2023. Revenue recognized under the GSK and Takeda collaborations in the second quarter of 2023 was $22.1 million. During the second quart”

Wave Life Sciences Ltd. reported financial results for the quarter ended March 31, 2023.

“On May 3, 2023, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2023.”

Wave Life Sciences Ltd. reported financial results for the quarter and year ended December 31, 2022.

“On March 22, 2023, Wave Life Sciences Ltd. announced its financial results for the quarter and year ended December 31, 2022.”

Wave Life Sciences Ltd. entered into Investor Agreement with Glaxo Group Limited (effective 2023-01-26).

“On January 26, 2023, as a condition to and simultaneous with the closing of the equity issuance contemplated by the Share Purchase Agreement (the “Share Purchase Agreement”), dated December 13, 2022, by and between Wave Life Sciences Ltd. (including its subsidiaries, the “Company” or “Wave”) and Glaxo Group Limited (“GGL”), the Company entered into an Investor Agreement with GGL (the “Investor Agreement”).”

Wave Life Sciences Ltd. entered into Share Purchase Agreement with Glaxo Group Limited ("GGL") valued at approximately $50 million (effective 2022-12-13).

“In connection with the parties’ entry into the Collaboration Agreement, the Company has agreed to sell to Glaxo Group Limited (“ GGL ”), an affiliate of GSK, 10,683,761 ordinary shares, no par value (the “ Ordinary Shares ”), for aggregate cash consideration of approximately $50 million, or $4.68 per Ordinary Share (the “ Equity Investment ”), pursuant to the terms of a Share Purchase Agreement, dated December 13, 2022, by and between GGL and the Company (the “ Share Purchase Agreement ”).”

Wave Life Sciences Ltd. entered into Collaboration and License Agreement with GlaxoSmithKline Intellectual Property (No. 3) ("GSK") valued at $170 million (effective 2022-12-13).

“On December 13, 2022, Wave Life Sciences USA, Inc. and Wave Life Sciences UK Limited (collectively, “ Wave ”), each direct, wholly-owned subsidiaries of Wave Life Sciences Ltd. (the “ Company ”) entered into a Collaboration and License Agreement (the “ Collaboration Agreement ”) with GlaxoSmithKline Intellectual Property (No. 3) (“ GSK ”).”

Wave Life Sciences Ltd. reported financial results for the quarter ended September 30, 2022.

“On November 10, 2022, Wave Life Sciences Ltd. (the “Company”) announced its financial results for the quarter ended September 30, 2022.”

Anne-Marie Li-Kwai-Cheung was appointed as Chief Development Officer at Wave Life Sciences Ltd..

“Effective as of October 14, 2022, Anne-Marie Li-Kwai-Cheung will be promoted to Chief Development Officer and will assume the Development responsibilities currently held by Dr. Panzara.”

Michael Panzara resigned as Chief Medical Officer, Head of Therapeutics Discovery and Development at Wave Life Sciences Ltd..

“On September 21, 2022, Michael Panzara, M.D., MPH, Chief Medical Officer, Head of Therapeutics Discovery and Development of Wave Life Sciences Ltd. (the “Company”), resigned effective as of October 14, 2022 to pursue another opportunity.”